Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

In 2023, sales from Novo Nordisk's GLP-1 diabetes therapies grew 52% year over year. Ozempic and a sibling treatment called Rybelsus are to thank for that growth.

Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...